Document is current
Any future updates will be listed below
-
Authors
Zhavoronkov, Alex https://orcid.org/0000-0001-7067-8966
Galkin, Fedor https://orcid.org/0000-0002-5709-9529
Chen, Shan
Ren, Feng https://orcid.org/0000-0001-9157-9182
Aliper, Alex
Durymanov, Mikhail
Sidorenko, Denis
Cui, Hui
Han, Jing-Dong J. https://orcid.org/0000-0002-9270-7139
Xu, Hao
Liu, Xiaodong https://orcid.org/0000-0002-9315-3406
Xu, Zuojun
Kuppe, Christoph https://orcid.org/0000-0003-4597-9833
Austin Argentieri, M. https://orcid.org/0000-0003-0242-853X
Ying, Kejun
Goeminne, Ludger J. E. https://orcid.org/0000-0002-8285-7766
Moqri, Mahdi https://orcid.org/0000-0001-6675-0566
Tyshkovskiy, Alexander https://orcid.org/0000-0002-6215-190X
Gladyshev, Vadim N. https://orcid.org/0000-0002-0372-7016
- License Information
-
More Information
Article History
Received: 17 November 2025
Accepted: 29 July 2026
First Online: 7 September 2026
Ethics
Competing interests: A.Z. is the founder and chief executive officer of Insilico Medicine, a publicly traded (3696.HK) company developing and using generative AI for drug discovery and aging research. F.G., S.C., F.R., A.A, M.D., D.S. and H.C. are employees at Insilico Medicine. Insilico Medicine has developed a portfolio of therapeutic programs targeting fibrotic diseases, including rentosertib for IPF. The other authors declare no competing interests.
